This phenomenon, in a similar manner to that seen in NSCLC, has been observed in a blinded molecular analysis of a Gynecologic Oncology Group (GOG) phase II trial in ovarian cancer with another EGFR inhibitor, gefitinib (Schilder et al, 2005). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.